Alivus Life Sciences Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

July 3, 2026
Posted by: Kunal Singla
Category: News

Alivus Life Sciences CMP Rs.1,179. Market cap Rs.14,232 Cr. PE 25.2. 12-month target Rs.1,190-1,344.

Alivus Life Sciences Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Alivus Life Sciences shares trading at Rs.1,179 against a market capitalisation of Rs.14,232 Cr and a price-to-earnings multiple of 25.2. As an industrials and capital goods name on the NSE and BSE, Alivus Life Sciences enters the Alivus Life Sciences Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

Quarterly financials for Alivus Life Sciences are not yet fully available on Univest’s data partners for this cycle; investors should track Screener.in and the NSE/BSE filings directly for the Alivus Life Sciences Q1 Results FY27 result date and cross-check any figures before making investment decisions.

Get Free Investment Predictions and Alivus Life Sciences Research at Univest

Alivus Life Sciences (NSE: ALIVUS) operates in the industrials and capital goods space and is tracked on Univest under its NSE and BSE listings ahead of the Alivus Life Sciences Q1 Results FY27 season, forming the base against which the Alivus Life Sciences Q1 Results FY27 estimates in this article are built. This Alivus Life Sciences Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Table of Contents

Alivus Life Sciences Q1 FY27 Estimates

Metric	Detail
CMP	Rs.1,179
Market Cap	Rs.14,232 Cr
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.1,190-1,344

Univest, a SEBI-Registered Investment Advisor, Tracks Alivus Life Sciences Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. Order Book Execution

Healthy order book execution translating into revenue recognition for the quarter is one of the primary variables that analysts are tracking ahead of Alivus Life Sciences’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Alivus Life Sciences share price target or faces renewed pressure.

2. Capex Revival in User Industries

Capex revival in core user industries supporting fresh order inflows is one of the primary variables that analysts are tracking ahead of Alivus Life Sciences’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Alivus Life Sciences share price target or faces renewed pressure.

3. Operating Leverage

Operating leverage on higher volumes aiding margin expansion versus last year is one of the primary variables that analysts are tracking ahead of Alivus Life Sciences’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Alivus Life Sciences share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Alivus Life Sciences’s live price and Q1 FY27 result updates.

Key Risks to the Alivus Life Sciences Q1 Results FY27 Outlook

Order execution delays pushing revenue recognition to later quarters.
Raw material and input cost inflation pressuring margins.
Slower capex recovery in key end-user industries affecting order inflows.

Q4 FY26 Performance Context

Detailed Q4 FY26 financials for Alivus Life Sciences were not available from Univest’s data partners at the time of writing. Investors should check Screener.in or the company’s exchange filings for the latest verified numbers before the Q1 FY27 results.

Technical Analysis Ahead of Alivus Life Sciences Q1 Results FY27

Alivus Life Sciences shares last traded at Rs.1,179. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Alivus Life Sciences Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Alivus Life Sciences Q1 Results FY27 trailing-growth framework points to a range of Rs.1,156-1,251 for Alivus Life Sciences, contingent on the Alivus Life Sciences Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Alivus Life Sciences Q1 Results FY27 view for Alivus Life Sciences works out to Rs.1,190-1,344, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into Alivus Life Sciences Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Alivus Life Sciences Q1 Results FY27 analysis would put Alivus Life Sciences in a Rs.1,256-1,469 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Alivus Life Sciences Q1 Results FY27 Print

Revenue and PAT versus the Alivus Life Sciences Q1 Results FY27 estimate range in this preview.
Management commentary on FY27 growth guidance and margin trajectory relevant to the Alivus Life Sciences Q1 Results FY27 narrative.
Healthy order book execution translating into revenue recognition for the quarter
Order execution delays pushing revenue recognition to later quarters

Conclusion on Alivus Life Sciences Q1 Results FY27

Alivus Life Sciences enters the Q1 FY27 results season trading at Rs.1,179, with the 12-month Uniresearch target range of Rs.1,190-1,344 reflecting a tracking stance. Investors tracking the Alivus Life Sciences Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Alivus Life Sciences Q1 Results FY27

When are Alivus Life Sciences Q1 FY27 results expected?

Ans. Alivus Life Sciences’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Alivus Life Sciences Q1 FY27 revenue estimate?

Ans. Detailed quarterly estimates are not available for Alivus Life Sciences at this time; check Screener.in or the company’s exchange filings for verified numbers.

What is the Alivus Life Sciences share price target?

Ans. The 12-month Uniresearch estimate for Alivus Life Sciences share price target is Rs.1,190-1,344, based on trailing growth and current valuation multiples.

Is Alivus Life Sciences a good buy before Q1 FY27 results?

Ans. Alivus Life Sciences is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Alivus Life Sciences’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and healthy order book execution translating into revenue recognition for the quarter.

Where can I track Alivus Life Sciences share price live?

Ans. Alivus Life Sciences share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.